Co-Diagnostics (NASDAQ:CODX) reported Q1 EPS of $0.34, $0.17 better than the analyst estimate of $0.17. Revenue for the quarter came in at $22.7 million versus the consensus estimate of $20.17 million.
Co-Diagnostics (NASDAQ:CODX) reported Q1 EPS of $0.34, $0.17 better than the analyst estimate of $0.17. Revenue for the quarter came in at $22.7 million versus the consensus estimate of $20.17 million.